Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Ordinary Shares, NIS 1.80 par value per share
-
Shares outstanding
-
5,591,387
-
Total 13F shares
-
72,824
-
Share change
-
-3,163
-
Total reported value
-
$102,011
-
Price per share
-
$1.38
-
Number of holders
-
13
-
Value change
-
-$18,462
-
Number of buys
-
3
-
Number of sells
-
7
Institutional Holders of Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (GLMD) as of Q3 2025
As of 30 Sep 2025,
Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (GLMD) was held by
13 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
72,824 shares.
The largest 10 holders included
CITADEL ADVISORS LLC, TWO SIGMA INVESTMENTS, LP, UBS Group AG, MORGAN STANLEY, Wealthspire Advisors, LLC, SBI Securities Co., Ltd., Federation des caisses Desjardins du Quebec, WELLS FARGO & COMPANY/MN, OSAIC HOLDINGS, INC., and TD Waterhouse Canada Inc..
This page lists
13
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.